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Abstract
Background: Vaccine development in the post-genomic era often begins with the in silico
screening of genome information, with the most probable protective antigens being predicted
rather than requiring causative microorganisms to be grown. Despite the obvious advantages of
this approach – such as speed and cost efficiency – its success remains dependent on the
accuracy of antigen prediction. Most approaches use sequence alignment to identify antigens.
This is problematic for several reasons. Some proteins lack obvious sequence similarity, although
they may share similar structures and biological properties. The antigenicity of a sequence may
be encoded in a subtle and recondite manner not amendable to direct identification by sequence
alignment. The discovery of truly novel antigens will be frustrated by their lack of similarity to
antigens of known provenance. To overcome the limitations of alignment-dependent methods,
we propose a new alignment-free approach for antigen prediction, which is based on auto cross
covariance (ACC) transformation of protein sequences into uniform vectors of principal amino
acid properties.
Results: Bacterial, viral and tumour protein datasets were used to derive models for prediction
of whole protein antigenicity. Every set consisted of 100 known antigens and 100 non-antigens.
The derived models were tested by internal leave-one-out cross-validation and external
validation using test sets. An additional five training sets for each class of antigens were used to
test the stability of the discrimination between antigens and non-antigens. The models
performed well in both validations showing prediction accuracy of 70% to 89%. The models were
implemented in a server, which we call VaxiJen.
Conclusion: VaxiJen is the first server for alignment-independent prediction of protective
antigens. It was developed to allow antigen classification solely based on the physicochemical
properties of proteins without recourse to sequence alignment. The server can be used on its
own or in combination with alignment-based prediction methods. It is freely-available online at
the URL: http://www.jenner.ac.uk/VaxiJen.
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Vaccination is a highly effective approach to disease con-
trol in human and veterinary health care. A vaccine is a
molecular or supramolecular agent which elicits specific,
protective immunity; that is an enhanced adaptive
immune response to re-infection by pathogenic microbes
through the potentiation of immune memory. Vaccina-
tion ultimately mitigates the effect of subsequent infec-
tion and disease. Thus, the immune system recognizes
vaccine agents as foreign, destroys them, and subse-
quently 'remembers' them. When the pathogenic micro-
organism is encountered again, the immune system has
been primed to respond, by neutralizing the target before
it can enter cells, or/and by destroying infected cells before
the microorganism can grow and cause damage. Vaccines
have contributed to the eradication of smallpox, the near
eradication of polio, and the control of a variety of dis-
eases, including rubella, measles, mumps, chickenpox,
typhoid [1].
Vaccines from the pre-genomic era were based on killed or
live, but attenuated, microorganisms, or subunits purified
from them [2]. Subunit vaccines contain one or more pure
or semi-pure antigens. In order to develop subunit vac-
cines, it is critical to identify those proteins which are
important for inducing protection and to eliminate oth-
ers. An antigen is said to be protective if it is able to induce
protection from subsequent challenge by a disease-caus-
ing infective agent in an appropriate animal model fol-
lowing immunization. The empirical approach to sub-
unit vaccine development, which includes several steps,
begins with pathogen cultivation, followed by purifica-
tion into components, and then testing of antigens for
protection [3]. Apart from being time- and labour-con-
suming, this approach has several limitations that can
lead to failure. Vaccines can not be developed using this
approach for microorganisms which can not easily be cul-
tured and only allows for the identification of those anti-
gens which can be obtained in sufficient quantities. In
some cases, the most abundant proteins are not immuno-
protective. In other cases, the antigen expressed during in
vivo infection is not expressed during in vitro cultivation.
Genomics has revolutionized vaccine research. The ability
to sequence the whole genome of a virulent microorgan-
ism has led some to screen in silico for the most probable
protective antigens before undertaking confirmatory
experiments. This approach, known as reverse vaccinol-
ogy [4], was first used to identify antigens as potential can-
didate vaccines against serogroup B meningococcus [5].
Apart from obvious advantages – such as speed and low
cost – the success of this approach is dependent on the
accuracy of antigen prediction, and many bioinformatics
tools are available to facilitate this process [6-8]. They can
identify surface-associated or outer membrane proteins,
signal peptides, lipoproteins, or host-cell binding
domains. Most algorithms use sequence alignment to
identify antigens. This is problematic for several reasons.
Some proteins formed through divergent or convergent
evolution lack obvious sequence similarity, although they
may share similar structures and biological properties [9].
In such a situation, alignment-based approaches may pro-
duce ambiguous results or fail. Moreover, antigenicity, as
a property, may be encoded in a sequence in a subtle and
recondite manner not amendable to direct identification
by sequence alignment. Likewise, the discovery of truly
novel antigens will be frustrated by their lack of similarity
to antigens of known provenance.
To overcome the limitations of alignment-dependent
sequence similarity methods, we propose a new align-
ment-independent method for antigen prediction based
on auto cross covariance (ACC) transformation of protein
sequences into uniform equal-length vectors. ACC is an
protein sequence mining method developed by Wold et
al. [10], which has been applied to quantitative structure-
activity relationships (QSAR) studies of peptides with dif-
ferent length [11,12] and for protein classification [13].
The ACC transformation accounts for neighbour effects,
i.e. the lack of independence between different sequence
positions. In the present study, we applied ACC pre-
processing to sets of known bacterial, viral and tumour
antigens and developed alignment-independent models
for antigen recognition based on the main chemical prop-
erties of amino acid sequences. The principal properties of
the amino acids were represented by z descriptors, origi-
nally derived by Hellberg et al. [14] to describe amino acid
hydrophobicity, molecular size and polarity. The models
were implemented in a server for the prediction of protec-
tive antigens and subunit vaccines, which we call VaxiJen.
This is freely accessible via the World Wide Web. Our
method is the first alignment-free bioinformatics tool for
the in silico identification of antigens.
Results
Three datasets were used in this study: one for bacteria,
one for viruses, and one for tumours. Each set consisted of
100 known antigens and 100 non-antigens, collected as
described in the Methods section. Each amino acid in the
protein sequence was represented by three z descriptors:
z1, z2, and z3. Each protein was transformed into a uniform
vector, which consisted of 45 ACC terms, by applying
ACC pre-processing, as described in the Methods section.
The new matrices were imported into SIMCA-P 8.0 [15]
and were subject to a two-class discriminant analysis
using the partial least squares technique (DA-PLS). The
models were validated using leave-one-out cross-valida-
tion (LOO-CV) on the whole sets and by external valida-
tion using test sets. The test sets were selected randomly to
include 25% of the whole sets. Then models were devel-Page 2 of 7
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excluded proteins. The validation results were assessed in
terms of AUCROC, accuracy, sensitivity and specificity, as
described in the Methods section. Additionally, five nega-
tive sets were compiled, and subsequently combined with
the positive set to generate five new training sets. They
also underwent DA-PLS and their AUCROC, accuracy, sensi-
tivity and specificity are given as mean values. Within the
server, the final model for each type was derived as a mean
of the best five models, as assessed by LOO-CV.
VaxiJen model for prediction of protective bacterial 
antigens
The LOO-CV of the bacterial model had 82% accuracy,
91% sensitivity and 72% specificity (Table 1). As expected,
the external validation showed a lower value but was still
satisfactory. The ROC curves are shown in Figure 1. The
average values for the additional sets were very close to
those derived for the initial model.
VaxiJen model for prediction of protective viral antigens
The viral model performed very well in the LOO-CV (87%
accuracy); performance in the external validation was
more moderate (70% accuracy at threshold 0.4) (Table 1).
ROC curves of the viral model validation are shown in Fig-
ure 2. The additional training sets showed lower mean
accuracy, sensitivity and specificity.
VaxiJen model for prediction of tumour antigens
The tumour model had excellent performance both in the
LOO-CV and in the external validation, exhibiting more
than 85% accuracy. The ROC curves are shown in Figure 3.
The additional models had lower sensitivity but similar spe-
cificity and accuracy.
Sequence similarity of training set
Potential similarity between sequences in the antigen and
non-antigen sets was assessed as described. The viral and
bacterial protective antigen sequence sets show very little
sequence similarity. This reflects their diverse species ori-
gins. The tumour set, derived from a single proteome,
exhibits a higher internal degree of self-similarity, but is
still clearly highly diverse.
VaxiJen server
The LOO-CV bacterial, viral and tumour models were
included in the VaxiJen server. Protein sequences can be
submitted as single proteins or uploaded as a multiple
sequence file in fasta format. A single target organism can
be selected. Additionally, ACC coefficients can be output.
This option makes the server useful for general ACC calcu-
lations of proteins. The results page lists the selected tar-
get, the protein sequence, its prediction probability, and a
statement of protective antigen or non-antigen, according
to a predefined cutoff. Since more of the models had their
highest accuracy at a threshold of 0.5, this threshold value
was chosen for all types.
Discussion
VaxiJen is the first server for alignment-independent pre-
diction of protective antigens of bacterial, viral and
tumour origin. The server contains models derived by
ACC pre-processing of amino acids properties. The predic-
tive ability of our models was tested by internal leave-one-
out cross-validation on training sets and by external vali-
dation on test sets. Accuracies of internal and external val-
idation for the three models lie in the range 70% to 89%.
The models showed remarkable stability, as tested by
combinations of the positive set and five different nega-
tive sets. Thus, VaxiJen is a reliable and consistent tool for
the prediction of protective antigens. It can be used singly
or in combination with other bioinformatics tools used
for reverse vaccinology.
The z descriptors are highly condensed descriptors, and
are derived from a principal component analysis (PCA) of
Table 1: VaxiJen models validation.
model validation AUCROCa thresholdb accuracy%c sensitivity%d specificity%e
LOO-CV 0.883 0.5 80 79 81
bacterial test set 0.726 0.5 70 76 64
LOO-CV (mean)g 0.899 0.5 83 81 85
LOO-CV 0.937 0.5 87 91 82
viral test set 0.743 0.4 70 84 56
LOO-CV (mean)g 0.810 0.5 73 74 71
LOO-CV 0.964 0.5 89 94 84
tumour test set 0.930 0.5 86 96 76
LOO-CV (mean)g 0.911 0.5 82 78 86
aThe area under the curve (AUCROC) is a quantitative measure of the predictive ability and varies from 0.5 for a random prediction to 1.0 for a 
perfect prediction.
bThe threshold of the highest accuracy.
cAccuracy = (true antigens + true non-antigens)/total.
dSensitivity = true antigens/all antigens.
eSpecificity = true non-antigens/all non-antigens.
gMean values of five training sets.Page 3 of 7
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of the twenty naturally occurring amino acids. They corre-
spond to the first three principal components explaining
the variance in the set [14]: z1 represents hydrophobicity,
z2 steric properties, and z3 polarity of the amino acids.
Since their creation, z descriptors have been widely used
for the characterization [16] and classification [13] of pro-
teins, and in QSAR studies on peptides [17,18]. Recently,
we have found that z descriptors are good predictors of
MHC binding peptides [19,20]. In the present study, z
descriptors represent the main physicochemical proper-
ties important for the recognition of antigens.
ACC transformations were used to remove irrelevant
information, such as sequence length, and to amplify the
class-discriminating properties [10]. Sjostrom et al [16]
applied the ACC transformation to z scale values in order
to assign successfully the subcellular location of bacterial
proteins (i.e. cytoplasmic, inner membrane, periplasm, or
outer membrane). More recently, a similar method was
applied to G-protein coupled receptors (GPCRs) and suc-
ceeded in classifying them into their major classes [13]. As
antigenicity is not a simple, readily-interpreted linear
property, it is unsurprising that ACC pre-processing of the
physicochemical properties of antigens and non-antigens
allows for a good discrimination between them. The rec-
ognition of protective antigens arises synergistically from
a combination of intermolecular interactions which
involves a diverse variety of underlying features – steric,
electrostatic and hydrophobic – which are explained well
by the three z descriptors.
The most important result of the present work is the abil-
ity of the models to predict whether a protein sequence
will, or will not, be a protective antigen. Such antigens
form the basis of subunit vaccines. In order to facilitate
the use of the derived models, a server, named VaxiJen,
was developed to allow users to assess a protein's ability
to induce protection. The server deals with single proteins
as well as whole proteomes submitted in fasta format. As
the method is general, models for parasite and fungal
antigens will be developed in the future and included in
the VaxiJen server.
Conclusion
VaxiJen is the first server for alignment-independent pre-
diction of protective antigens. It was developed to allow
antigen classification based solely on the physicochemical
properties of the protein irrespective of sequence length
and the need for alignment. VaxiJen is an open system:
new models will be included in the future, old ones will
be improved. The server can be used singly or in combina-
tion with alignment-dependent prediction methods.
Methods
Protein datasets
Three datasets were used: one for bacteria, one for viruses
and one for tumours. The sets are given as part of Addi-
tional Material. Each set consists of 100 known antigens
ROC curves for VaxiJen tumour modelFigure 3
ROC curves for VaxiJen tumour model.
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ROC curves for VaxiJen bacterial model.
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ROC curves for VaxiJen viral modelFigure 2
ROC curves for VaxiJen viral model.
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were collected from the literature. A protein was identified
as an antigen if it (or part of it) has been shown to induce
a protective response in an appropriate animal model
after immunization. Tumour antigens were collected from
the SEREX database available within the Cancer Immu-
nome Database [21].
The sets of non-antigens were constructed to mirror the
antigen sets. The bacterial non-antigen set contained pro-
teins randomly selected from the same set of species. The
viral non-antigen set was compiled from viral proteomes
downloaded from the Viral Bioinformatics Resource
Center [22]. Because, on average, viral genomes are so
small, a variant method was used to select non-antigens.
Proteins were selected at random, but care was taken that
sequences were not obviously related at the sequence level
to members of the positive set or to each other. A BLAST
expectation value of 3.0 was used: sequences were only
accepted which had a value more positive than this cutoff.
As each new sequence was assessed, it was compared to
both the positive set of known antigens and the growing
list of non-antigens. The tumour non-antigen set included
randomly chosen human proteins. Proteomes and pro-
tein sequences were obtained from the UniProt Knowl-
edgebase of the ExPASy Proteomics Server [23]. For the
external validation of the three models, test sets of 25 anti-
gens and 25 non-antigens were selected by picking every
fourth protein in the database sorted alphabetically
according to the protein swiss-prot number, vprcpep ID,
or SEREX ID. To test the stability of the models, five addi-
tional negative sets for each kingdom were compiled algo-
rithmically. These sets were combined with the
corresponding positive set to generate five new training
sets. These sets underwent the same DA-PLS and the
derived models were compared with the initial one in
terms of AUCROC, accuracy, sensitivity and specificity. The
three positive sets are available as supplementary material
[see Additional file 1].
z descriptors
The z descriptors, defined by Hellberg and collaborator
[14], summarize the principal physicochemical properties
of the amino acids. These descriptors were derived by
principal component analysis of a data matrix consisting
of 29 molecular descriptors, like molecular weight, pKas,
13C NMR shifts, etc. The first principle component (z1)
reflects the hydrophobicity of amino acids, the second
(z2) their size, and the third (z3) their polarity. By arrang-
ing the z values according to the amino acid sequence, it
is possible to quantify the structural variations numeri-
cally within a series of related proteins. In the present
study the z1, z2 and z3 descriptors were used to describe the
protein sequences.
Auto cross covariance (ACC) pre-processing
As the proteins used in the study had different lengths, an
auto cross covariance (ACC) transformation was used to
transform them to a uniform length. The auto covariance
Ajj(lag) was calculated according to Eqn. (1) [10]:
Index j was used for the z-scales (j = 1, 2, 3), n is the
number of amino acids in a sequence, index i is the amino
acid position (i = 1, 2, ...n) and l is the lag (l = 1, 2, ...L).
In order to investigate the influence of close amino acid
proximity on protein antigenicity, a short range of lags (L
= 1, 2, 3, 4, 5) were used. Cross covariances – Cjk(lag) –
between two different z-scales, j and k, were calculated
according to Eqn. (2) [10]:
The results of these transformations were new uniform
sets of 45 variables (32 × 5) for each protein.
Discriminant analysis by partial least squares (DA-PLS)
Two-class discriminant analysis by partial least squares
(DA-PLS), as implemented in SIMCA-P 8.0 [17], was
applied to the matrices, which consisted of 45 variables
and 200 observations (100 antigens + 100 non-antigens).
The optimum number of components was selected by
adding components until the next component to be
added explained less than 10% of the variance. The pre-
dictive accuracy of the models was measured by leave-
Ajj l
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: Similarities between sequences in the three training sets.
Model Type Number of 
clusters
Minimum 
cluster size
Maximum 
cluster size
Number of 
Singletons
Average cluster 
size
Cluster 
distributiona
Bacterial 84 1 4 74 1.19 6,2,2
Viral 87 1 5 78 1.15 7,1,0,1
Tumour 76 1 7 66 1.32 4,2,2,1,0,1
For a given cut-off, a perfectly diverse set of sequences will have number of clusters equal to the number of sequences, a maximum and minimum 
cluster size of one, and an average cluster size of one.
a for non-singleton clusters of 2 or more members. Cluster numbers are shown in ascending cluster size.Page 5 of 7
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by external validation on the test set using Receiver Oper-
ating Characteristic (ROC) curves [26]. The correctly pre-
dicted antigens and non-antigens were defined as true
positives (TP) and true negatives (TN), respectively, while
the incorrectly predicted antigens and non-antigens
yielded false negatives (FN) and false positives (FP),
respectively. Two variables – sensitivity [TP/(TP + FN)] and
1-specificity [FP/(TN + FP)] – were calculated at different
thresholds and ROC curves were generated [24]. The area
under the curve (AUCROC) is a quantitative measure of the
predictive ability and varies from 0.5 for a random predic-
tion to 1.0 for a perfect prediction. Prediction accuracy
[(TP + TN)/total] at different thresholds was also calcu-
lated.
Sequence similarity of training set
Potential similarity between sequences in the antigen and
non-antigen sets could bias the LOO-CV. Using a standard
cutoff [25], all sequences from the positive set were com-
pared against all other positive sequences using BLAST
[6]. Using lists of hits to define nearest-neighbour connec-
tions, the algorithm of Floyd [26] was used to cluster the
sequences. The results are shown in Table 2.
VaxiJen server
The VaxiJen server [27] is implemented in Perl, with an
interface written in HTML. VaxiJen identifies bacterial,
viral and tumour antigens using three different models,
derived in the present study. Protein sequences are
uploaded as single or multiple files in plain or fasta for-
mat respectively. The results page reports antigen proba-
bility (as a fraction of unity) for each protein and a
statement of antigen status ("probable Antigen" versus
"Probable Non-Antigen").
Availability and requirements
Project name: VaxiJen
Project home page: http://www.jenner.ac.uk/VaxiJen
Operating system(s): IRIX, Linux, Windows
Programming language: Perl
Other requirements: none
License: free
Any restrictions to use by non-academics: none
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